tiprankstipranks
Entrada Therapeutics reports Q3 EPS (35c), consensus (73c)
PremiumThe FlyEntrada Therapeutics reports Q3 EPS (35c), consensus (73c)
2M ago
Is TRDA a Buy, Before Earnings?
Premium
Pre-Earnings
Is TRDA a Buy, Before Earnings?
2M ago
Entrada Therapeutics presents new data on expanding Duchenne Franchise
Premium
The Fly
Entrada Therapeutics presents new data on expanding Duchenne Franchise
2M ago
Entrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
PremiumCompany AnnouncementsEntrada Therapeutics’ Promising Phase 1 DMD Drug Trial Results
6M ago
Entrada Therapeutics reports ‘positive’ data from Phase 1 ENTR-601-44-101 trial
Premium
The Fly
Entrada Therapeutics reports ‘positive’ data from Phase 1 ENTR-601-44-101 trial
6M ago
Two new option listings on May 30th
Premium
The Fly
Two new option listings on May 30th
7M ago
Entrada Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyEntrada Therapeutics initiated with an Outperform at Oppenheimer
12M ago
Entrada Therapeutics promotes Dowden to President
Premium
The Fly
Entrada Therapeutics promotes Dowden to President
12M ago
Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
Premium
The Fly
Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100